How Has the Pancreaze (Pancrelipase) Market Evolved Historically and What is its Current Size?
The pancreaze pancrelipase market has seen considerable growth due to a variety of factors.
• The market size of pancreaze (pancrelipase) has considerably expanded in recent years, expected to rise from $1566.86 million in 2024 to $1660.16 million in 2025, with a compound annual growth rate (CAGR) of 6.0%.
This growth during the historical period can be tied to several factors including the increased occurrence of exocrine pancreatic insufficiency (epi), the growing age of the population, advancements in treatment options, a rise in cases of pancreatic cancer, and the worldwide expansion of healthcare services.
What Is The Projected Growth Of The Pancreaze (Pancrelipase) Template Market?
The pancreaze pancrelipase market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the pancreaze (pancrelipase) market is projected to experience substantial growth, reaching $2063.36 million by 2029 at a compound annual growth rate (CAGR) of 5.6%.
The anticipated growth for the forecast period is due to the escalating incidence of pancreatic diseases, ongoing research and clinical trials, augmented access to global healthcare, enhancements in healthcare infrastructure, and government-led initiatives along with reimbursement policies. Key trends in the forecast period encompass improvements in enzyme delivery systems, technological upgrades, the inclusion of digital health strategies, a rise in collaborations, and the production of enteric-coated formulations.
What Are The Key Drivers Fueling Growth In The Pancreaze (Pancrelipase) Market?
The growth of the pancreaze (pancrelipase) market is believed to be fuelled by the upsurge in cases of cystic fibrosis. Cystic fibrosis is a hereditary disease that impacts the lungs, digestive system, and other organs, resulting in the secretion of dense, viscous mucus that can lead to obstructions, infections, and malfunctioning. The escalation in cystic fibrosis cases is primarily attributed to greater awareness, improved diagnostic strategies, and broadened genetic screening programs that identify a higher number of previously undetected cases, including milder forms. Pancreaze (pancrelipase) is utilized in cystic fibrosis management to aid digestion by substituting enzymes that the pancreas fails to efficiently generate, thereby assisting patients in absorbing nutrients from food and enhancing overall nutritional health. The Cystic Fibrosis Trust, a UK-based charity organization that supports individuals with cystic fibrosis, reported in October 2024 that 11,148 cystic fibrosis patients were registered in 2022 and this number escalated to 11,318 in 2023, signifying a 1.5% annual increase in patient registrations. Consequently, the escalations in cystic fibrosis cases are fuelling the expansion of the pancreaze (pancrelipase) market.
What Are The Principal Market Segments In The Global Pancreaze (Pancrelipase) Industry?
The pancreaze (pancrelipase) market covered in this report is segmented –
1) By Type: Capsule, Tablet
2) By Age: Children, Adults, Geriatrics
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Chronic Pancreatitis, Cystic Fibrosis, Other Applications
Pre-Book The Pancreaze (Pancrelipase) Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Pancreaze (Pancrelipase) Market?
One significant trend observed in the pancreaze (pancrelipase) market revolves around the growing emphasis on presenting clinical evidence that supports the effectiveness of a drug, typically using data obtained from clinical trials. This data is instrumental in expediting regulatory approval processes, bolstering patient outcomes, and solidifying a drug's competitive standing in the market. For example, in May 2024, Vivus, Inc., a biopharmaceutical company based in the US, unveiled the results from recent clinical trials showcasing the power of PANCREAZE (pancrelipase) in maintaining weight for chemotherapy patients dealing with pancreatic ductal adenocarcinoma (PDAC), cachexia, and exocrine pancreatic insufficiency (EPI). The study also indicates that PANCREAZE could potentially reduce stool frequency as well as enhance stool consistency. The researchers from Cedars-Sinai Medical Center and the Samuel Oschin Cancer Center conducted the study as an investigator-initiated trial.
Who Are the Key Players In The Pancreaze (Pancrelipase) Market?
Major companies operating in the pancreaze (pancrelipase) market include:
• AbbVie Inc.
What Are The Regional Insights Into The Pancreaze (Pancrelipase) Market?
North America was the largest region in the pancreaze (pancrelipase) market in 2024. The regions covered in the pancreaze (pancrelipase) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
